DOWNLOAD THE GRAND CHALLENGES APP
Want all of the meeting details at your fingertips? Download the free Grand Challenges in Parkinson's Disease app by installing Whova from Google Play or the App Store. Once downloaded, search "Grand Challenges in Parkinson's Disease" and select "join." When prompted for an event code, please use **GCPD2016**.

Thank you to our sponsors!

LUNCH SPONSORS

Roche

US WorldMeds

SESSION SPONSORS

ACORDA THERAPEUTICS

ADAMAS™

Journal of Parkinson's Disease

BREAKFAST SPONSOR

abbvie

REFRESHMENT BREAK SPONSOR

GE

SUPPORTING SPONSORS

TEVA

MERCY HEALTH HAUENSTEIN NEUROSCIENCES

Renovo neural

Parkinson's Foundation, Parkinson's Disease Foundation Division

PROTEOS CONTRACT RESEARCH SERVICES

ThermoFisher SCIENTIFIC

ACADIA Pharmaceuticals

custer

ucb Inspired by patients. Driven by science.

Medtronic

GRAND CHALLENGES IN PARKINSON'S DISEASE

GENES & PATHWAYS | VAN ANDEL RESEARCH INSTITUTE

September 26–27, 2016

VAN ANDEL RESEARCH INSTITUTE

www.grandchallengesinpd.org

Monday, September 26, 2016

7:30 a.m. Continental breakfast

WELCOME AND JAY VAN ANDEL AWARD ADDRESS

8:30 a.m. Peter Jones, Ph.D., D.Sc.–Van Andel Research Institute, USA
Introduction of honoree Dr. Stanley Fahn

8:40 a.m. Stanley Fahn, M.D.–Columbia University, USA
Jay Van Andel Award for Outstanding Achievement in Parkinson's Disease Research
The revolutionary Rx for PD that almost got away: the levodopa story

9:40 a.m. Discussion

9:55 a.m. Break

GENE IDENTIFICATION: NOMINATING PATHWAYS AND MECHANISMS
SESSION CHAIR: Darren Moore, Ph.D.—Van Andel Research Institute

10:15 a.m. John Hardy, Ph.D., FMedSci, FRS–University College London, UK
Genetic risk for idiopathic PD: nominating pathways

10:45 a.m. Coro Paisàn-Ruiz, Ph.D.–Icahn School of Medicine at Mount Sinai, USA
Monogenic PD/Parkinsonism: new genes and pathways

11:15 a.m. Asa Abeliovich, M.D., Ph.D.–Columbia University, USA
Functional studies of Parkinson's disease risk factors

11:45 a.m. Haydeh Payami, Ph.D.–University of Alabama at Birmingham, USA
Gene-environment risk interactions in Parkinson's disease

12:15 p.m. Discussion

12:30 p.m. Lunch

ALPHA-SYNUCLEIN: BIOLOGY AND PATHOPHYSIOLOGY
SESSION CHAIR: Patrik Brundin, M.D., Ph.D.—Van Andel Research Institute

1:45 p.m. Abstract selected talk
Maxime W.C. Rousseaux, Ph.D.–Baylor College of Medicine, USA
TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau

2:00 p.m. Subhojit Roy, M.D., Ph.D.–University of Wisconsin, USA
Synaptic function and dysfunction of alpha-synuclein

2:30 p.m. Chris Dobson, FRS, FMedSci–University of Cambridge, UK
The molecular basis of Parkinson's disease and its therapeutic significance

3:00 p.m. Break

3:15 p.m. Kelvin Luk, Ph.D.–Perelman School of Medicine, University of Pennsylvania, USA
Molecular and biological determinants of alpha-synuclein seeding and transmission

3:45 p.m. Aaron Gitler, Ph.D.–Stanford School of Medicine, USA
Toxic mechanisms of alpha-synuclein in Parkinson's disease

4:15 p.m. Abstract selected talk
Nolwen Rey, Ph.D.–Van Andel Research Institute, USA
Widespread transneuronal propagation of alpha-synuclein triggered in the olfactory bulb mimics prodromal Parkinson's disease

4:30 p.m. Discussion

5:00 p.m. Poster session

7:15 p.m. Scientific networking dinner
Please note, attendees must be registered.

Tuesday, September 27, 2016

7:30 a.m. Continental breakfast

LRRK2: FUNCTION AND NEUROTOXIC MECHANISMS
SESSION CHAIR: Jeremy Van Raamsdonk, Ph.D.—Van Andel Research Institute

8:30 a.m. Mark Cookson, Ph.D.–National Institute on Aging, National Institutes of Health, USA
Functional studies of LRRK2 activity, interactors and substrates

9:00 a.m. Andrew West, Ph.D.–University of Alabama at Birmingham, USA
Interplay between LRRK2 and alpha-synuclein

9:30 a.m. Jie Shen, Ph.D.–Harvard Medical School, USA
LRRK2 loss of function in Parkinson's disease

10:00 a.m. Darren Moore, Ph.D.–Van Andel Research Institute, USA
Mechanisms of LRRK2-dependent neurotoxicity in Parkinson's disease

10:30 a.m. Discussion

10:45 a.m. Break

MITOCHONDRIAL QUALITY CONTROL
SESSION CHAIR: Viviane Labrie, Ph.D.—Van Andel Research Institute

11:00 a.m. Wolfdieter Springer, Ph.D.–Mayo Clinic, USA
Parkin structure and activity

11:30 a.m. Edward (Ted) Fon, M.D., FRCP(C)–McGill University, Canada
Function of PINK1 and Parkin in mitochondrial control

12:00 p.m. Richard Youle, Ph.D.–National Institutes of Health, USA
Damage control: function of genes mutated in familial Parkinson's disease in mitochondrial maintenance

12:30 p.m. Discussion

12:45 p.m. Lunch

1:45 p.m. Report from Rallying to the Challenge

2:15 p.m. Brian Fiske, Ph.D.–The Michael J. Fox Foundation for Parkinson's Research, USA
Translating Parkinson's genetics into therapies for patients: a funder's perspective

VESICULAR TRAFFICKING AND TURNOVER
SESSION CHAIR: Jiyan Ma, Ph.D.—Van Andel Research Institute

2:45 p.m. Abstract selected talk
John Sanderson, B.A.–Harvard Medical School, USA
Characterization of soluble disease-associated alpha-synuclein species isolated from human brain tissue

3:00 p.m. Ellen Sidransky, M.D.–National Institutes of Health, USA
The lysosome and Parkinsonism: the glucocerebrosidase story

3:30 p.m. Zhenyu Yue, Ph.D.– Icahn School of Medicine at Mount Sinai, USA
Synaptic vesicle trafficking in PD

4:00 p.m. Matthew Seaman, Ph.D.–University of Cambridge, UK
Modulation of retromer function to rescue the PD-causing mutation

4:30 p.m. Abstract selected talk
William P. Flavin–Loyola University Chicago, USA
Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins

4:45 p.m. Discussion

5:00 p.m. Closing remarks